TAZIDIME Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tazidime, and what generic alternatives are available?
Tazidime is a drug marketed by Lilly and is included in two NDAs.
The generic ingredient in TAZIDIME is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tazidime
A generic version of TAZIDIME was approved as ceftazidime by ACS DOBFAR on November 20th, 1985.
Summary for TAZIDIME
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Patent Applications: | 6,887 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TAZIDIME at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for TAZIDIME
US Patents and Regulatory Information for TAZIDIME
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | TAZIDIME | ceftazidime | INJECTABLE;INJECTION | 062655-001 | Nov 20, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lilly | TAZIDIME IN PLASTIC CONTAINER | ceftazidime | INJECTABLE;INJECTION | 062739-002 | Jul 10, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lilly | TAZIDIME | ceftazidime | INJECTABLE;INJECTION | 062655-002 | Nov 20, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lilly | TAZIDIME IN PLASTIC CONTAINER | ceftazidime | INJECTABLE;INJECTION | 062739-001 | Jul 10, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |